Advertisement
Discovery Report
Artificial intelligence in drug discovery:
Hope or Hype?
ACS member exclusive
Illustration by Chris Gash

At the world’s pharma and biotech companies, artificial intelligence is increasingly critical to the drug discovery engine. A 2019 survey by the Pistoia Alliance found that 70% of life science researchers use AI, including machine and deep learning, in their work, up from 44% just two years earlier. But where along the road to a new drug will AI have the most impact? This Discovery Report examines the hope and the hype—and what scientists need to know to understand what’s next.


If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

This Discovery Report is an ACS member exclusive. LOG IN NOW TO READ

BECOME A MEMBER to download this report. You’ll also unlock unlimited access to all of C&EN.